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CObjectives: To examine the use and cost of health-care services in
British Columbia, Canada, before and after public drug coverage for
tiotropium bromide. Methods: A time series analysis was performed
sing data from British Columbia’s centralized administrative health-
are databases. Linear regression on data from a stable 3-year prepolicy
eriod was used to predict future use of inhaled anticholinergic (IAC)
edications, visits to physicians, emergency hospitalizations, and
osts. For each use measure, we estimated the policy effect as the
ifference between observed use in the postpolicy period and predicted
se obtained from the prepolicy period. Results: In total, over the 2.5-
year period after public coverage, tiotropium use increased by 24.4%
more than predicted (95% confidence interval [CI] 23.9%–24.8%). Visits
to physicians were unchanged, but there were between 596 and 948
more emergency admissions for chronic obstructive pulmonary dis-
ease, and between 582 and 1940 more hospital admissions of any kind
than were predicted from prepolicy data. Total cost of inhaled IAC O
Anes
2, Ca
al So
doi:10.1016/j.jval.2010.11.018edications increased slightly more than predicted, by between an
dditional CDN$1.30 million and CDN$1.71 million, but total out-of-
ocket spending by patients on IAC medications was reduced by be-
ween CDN$2.83 million and CDN$3.11 million because of public
overage. Hospital costs were between CDN$3.88 million and
DN$12.93 million greater than anticipated based on prepolicy data.
onclusions: Public drug plan coverage for tiotropium in British Co-
umbia reduced out-of-pocket costs for patients and their private in-
urers. Before versus after time series analysis did not show a reduc-
ion in hospitalizations or physician visits, or costs associated with
hose services.
eywords: chronic obstructive pulmonary disease, health-care use,
ealth services research, inhaled medications, pharmacoeconomics,
iotropium
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The public drug insurance plan in British Columbia (BC), Canada,
commonly known as PharmaCare, provided reimbursement for
tiotropium bromide beginning in July 2007. Tiotropium and ipra-
tropium are the most common inhaled anticholinergic (IAC) med-
ications indicated for the treatment of chronic obstructive pulmo-
nary disease (COPD). Coverage for tiotropium was offered subject
to a previous authorization process based on criteria for pulmo-
nary function and previous responsiveness to treatment with
ipratropium bromide. This article compares use and cost of
health-care services in IAC patients in BC before and after that
policy change.
Many drug plans use previous authorization policies to en-
courage cost-effective treatment choices when substantial price
differences exist among therapies [1]. Ipratropium was the most
commonly used IAC before the introduction of tiotropium. Ipra-
tropium is less expensive (CDN$32 per prescription in 2009 com-
pared to CDN$95 for tiotropium) and has been used for the treat-
ment of COPD for decades. The purpose of listing tiotropium
subject to prior authorization was to ensure that patients who
would otherwise have an adequate response to ipratropium would
Conflicts of interest: None.
* Address correspondence to: Colin R. Dormuth, Department of
Columbia, 1110 Government Street, Suite 210, Victoria, BC V8W 1Y
E-mail: colin.dormuth@ti.ubc.ca.
1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.still have the opportunity to do so before receiving the more ex-
pensive tiotropium, for which literature on its comparative thera-
peutic advantages over ipratropium is mixed. Tiotropium has
been reported in reviews of clinical trials to be both no more effec-
tive than ipratropium [2,3], and superior at reducing COPD exac-
erbations and related hospitalizations [4].
COPD is a debilitating disease that worsens with time and can
lead to death. Severe airflow obstruction and frequent exacerba-
tions are two factors that predict poorer prognosis and for which
drug therapy may help. Canadian guidelines state that there is
some evidence that tiotropium is more efficacious than ipratro-
pium for sustained improvements in pulmonary function, chronic
activity-related dyspnea, and health status [5]. Clinical trials, how-
ever, often use strict enrollment and exclusion criteria, and com-
pliance with treatment in trials is usually better than in usual
practice. For these reasons, the drug effects observed in clinical
trials do not necessarily translate to actual experience, and post-
market evaluations are important to make sure that the costs of
new treatments are worthwhile.
In our study, we conducted time series analyses on various
measures of health-care use, including IAC use, physician visits,
and hospitalizations. Time series analysis can be an informative
thesiology, Pharmacology & Therapeutics, University of British
nada.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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601V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 0 0 – 6 0 6method for estimating health-care use in a population. If use fol-
lows a stable pattern before a policy change, then the prepolicy
pattern can be used to predict future use without the need to mea-
sure all relevant factors that explain use in specific patients. De-
partures in use from expected trends in the postpolicy period can
then be viewed as possible consequences of the policy. In our
study, we used 3 years of prepolicy data to predict use during the
subsequent 2.5 years of PharmaCare coverage for tiotropium.
A priori expectations of the policy were an increase in use of
tiotropium above prelisting trends, a decrease in ipratropium use,
and spending on IACs by PharmaCare to increase while private
out-of-pocket spending decreased. If tiotropium provides superior
clinical response in some patients, then fewer visits to a physician
might also be a consequence of the policy. However, additional phy-
sician visits could also result from physicians initially monitoring
patients more closely after switching drugs [6]. We therefore did not
have a strong expectation for physician visits to change in any par-
ticular direction.
We expected hospitalizations for IAC patients to possibly de-
crease based on results of other studies. Meta-analyses of ran-
domized trials have provided some evidence that tiotropium may
reduce COPD-related hospitalizations or exacerbation-related
hospitalizations compared to placebo [4,7,8]. One of the meta-
analyses also reported a nonsignificant reduction in COPD-related
hospitalizations with tiotropium compared to salmeterol [4]. Two
placebo-controlled trials measured all-cause hospitalizations; one
found that tiotropium reduced all-cause hospitalizations [9],
whereas the other found no significant difference [10]. Another
placebo-controlled trial and a trial comparing tiotropium and ipra-
tropium found that tiotropium increased the time to first hospi-
talization for a COPD exacerbation [11]. One of two cohort studies
evaluating COPD hospitalizations found a decreased risk of COPD
referrals and hospitalizations with tiotropium compared to ipra-
tropium and salbutamol [12], whereas another found an increased
isk of hospitalizations associated with tiotropium use compared
o nonuse [13].
Methods
Drug coverage policy intervention for tiotropium
All residents of BC are eligible for drug coverage from the provin-
cial drug insurance program, commonly known as PharmaCare.
Some groups, such as patients on social income assistance, re-
ceive 100% coverage for eligible prescription costs, but the major-
ity of families have an income-based deductible of between 0% to
approximately 4% of family income, a 25% to 30% coinsurance
amount payable on prescriptions above the deductible, and an
annual out-of-pocket ceiling equal to approximately 1.25% to 4% of
income. PharmaCare covers all eligible costs above the ceiling [14].
Tiotropium was first dispensed in BC in 2003 and became eli-
gible for PharmaCare coverage under prior authorization starting
in July 2007. To qualify for coverage, a patient required a diagnosis
of COPD where forced expiratory volume in 1 second (FEV1) as a
percentage of predicted value was 65%, and the ratio of FEV1 to
forced vital capacity was 0.7. Inadequate response to a 3-month
trial of ipratropium at a dose of 12 puffs daily was also required.
Patients of respirologists could receive coverage without having to
satisfy the prior authorization criteria.
Data
Prescription records were obtained from PharmaNet, a centralized
database that contains records of all prescriptions dispensed at
community pharmacies in BC [15]. Prescriptions are captured in
the database regardless of who covers the cost, even if the patient
pays 100% out-of-pocket. Underreporting and misclassificationare assumed to be minimal because all community pharmacies
use PharmaNet and the system performs data quality checks
when claims are transmitted. These records were linked by en-
crypted personal health numbers to Ministry of Health adminis-
trative databases for physician services and hospitalizations.
These databases contained diagnostic codes (International Classi-
fication of Diseases [ICD] 9th revision for physician services, 10th
revision for hospitalizations) and dates of service or admission.
We assumed that completeness and misclassification of diagnos-
tic coding in the BC databases was comparable to other adminis-
trative health-care databases [16–20].
Use of IAC medications
The source population for the analysis of IAC use included all
residents of BC 45 years of age and older (1,670,000 in June 2004 and
1,931,000 in June 2009) who were not residents of a nursing home.
We extracted records for patients 45 years of age and older from
the PharmaNet database who were dispensed an IAC medication
(i.e., ipratropium or tiotropium) after June 30, 2004, and before
December 31, 2009. Nebulized and nasal IAC medications were
excluded, the former because they were not hand-actuated puff-
ers like tiotropium, and the latter because they are indicated for
rhinorrhea due to a common cold or allergies. Patients who were
previously in a nursing home were also excluded.
IAC medication prescriptions are not entirely consumed on the
day they are dispensed, and the dispensing date does not neces-
sarily coincide perfectly with timing of use. Dispensing records
were smoothed to more accurately reflect consumption. For each
patient and day in the study period, we calculated whether that
day was covered by a medication from a previous dispensing. Be-
ginning with a patient’s first observed dispensing, we constructed
a diary of use [21] assuming the patient consumed one defined
dose per day (daily dose) as established by the World Health Orga-
nization (WHO) [22]. For example, a patient dispensed 4000 g of
ipratropium (WHO daily dose  120 g) on January 15 was esti-
ated to consume 120 g each day for 33 days. Accordingly, the
atient was estimated to consume 17 daily doses in January and 16
n February. When a dispensing occurred before a patient’s previ-
us supply was estimated to end, use of the new dispensing was
ssumed to begin the day after the end of the previous supply.
hen a dispensing occurred after the estimated end of a previous
upply, then use of the new dispensing was assumed to begin on
he day it was dispensed. If at any time a patient accumulated an
stimated supply of180 daily doses, then the estimated end date
f the supply was shortened to 180 days. Supply end dates were set
o the date of cancellation of medical services coverage for pa-
ients who terminated coverage before their supply was estimated
o end. Estimates for individuals were then summed across the
hole population 45 years of age and older to produce an estimate
f total daily doses used per resident per month. The smoothing
lgorithm was not intended to be accurate for any single patient
ut instead to provide an accurate estimate of overall use in the
opulation when summed across all patients.
Physician visits and emergency COPD hospitalizations
The analysis of physician visits and hospital admissions was re-
stricted to patients who used tiotropium or ipratropium. This de-
nominator of patients included the person-time of all residents 45
years of age and older who were in a window of time after receiv-
ing their first prescription for an IAC medication in the study pe-
riod and before the earliest of 60 days past the end of their last
recorded IAC medication prescription, death, cancellation of med-
ical services coverage, or the end of the study period. We extracted
all emergency COPD hospital admissions and fee-for-service phy-
sician visits that occurred in each patient’s follow-up window. The
end of the study period was December 1, 2009, for physician visits
602 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 0 0 – 6 0 6and March 31, 2009, for emergency hospitalizations, which was
when our hospitalizations data ended.
Physician use was measured in visit-days, which was defined as
the number of days on which a patient visited a physician for any
reason. Patients with multiple services recorded on the same day
were counted as 1 visit-day. Emergency hospital admissions for
COPD consisted of all emergency admissions to acute care hospitals
where the primary reason for admission was COPD, defined by an
ICD-10 (ICD 10th Revision) code of J44.
Changes in health-care system costs
Each record in PharmaNet contains data on the cost of the prescrip-
tion, including ingredient costs (total costs as well as the amount
reimbursed by PharmaCare), dispensing fees, and occasionally spe-
cial services fees. We defined out-of-pocket cost as the difference
between total cost and paid cost. Data on private third party insur-
ance were unavailable, and some out-of-pocket costs were undoubt-
edly covered by private insurance plans.
The actual cost of hospital stays are not calculated in Canada. In-
stead, hospitals receive global funding from their provincial Ministry
of Health, and discharge records include a resource intensity weight
(RIW) that can be used to estimate cost. RIWs are calculated by the
Canadian Institute for Health Information. The RIW is an estimate of
the relative amount of resources used by a patient during a hospital
stay (detailed information on RIW methodology can be obtained
from www.cihi.ca). The British Columbia Ministry of Health Services
(MOHS) estimates a cost for one RIW by considering a number of
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Fig. 1 – Use of inhaled anticholinergic medications by reside
after provincial coverage of tiotropium bromide (July 2004–Decemfactors, including the total number of RIWs that a hospital accumu-
lated and the amount of funding it received. As of June 22, 2009, the
MOHS in British Columbia estimated the cost of one RIW in the fiscal
year 2008/09 to be CAN$5012.
Statistical analysis
For IAC use, physician visits and hospitalizations, linear regression
analysis was used to predict post-policy use based on pre-policy data.
In the analyses of IAC medication use, regression models were fit for
tiotropium use, ipratropium use, and total IAC medication use
(tiotropium and ipratropium). In each, the dependent variable was
the total number of daily doses used per resident. Independent vari-
ables included a linear time variable, sine and cosine terms for
month (with 12 months per period), and autoregressive terms to
compensate for autocorrelated disturbances.
The dependent variables in the physician visits and emergency
hospitalizations analyses were visit-days per patient per month
and admissions per patient per month, respectively. Independent
variables in the physician visits and emergency hospitalizations
models included a linear time variable, indicator variables for cal-
endar month (11 indicator variables in total) and autoregressive
terms to compensate for autocorrelated disturbances. In all re-
gression analyses, autoregressive lag terms were selected using a
backward stepwise autoregression method. Starting with a
model including 12 lags (one for each month of the year), lag
terms were sequentially removed until all remaining lags in a
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603V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 0 0 – 6 0 6regression model had significant t tests. Heteroscedasticity was
valuated using Lagrange multiplier tests.
In all analyses, predicted values and corresponding 95% confi-
ence limits were estimated from the regressions on prepolicy
ata. For each use component (IAC medication use, physician vis-
ts, and hospitalizations), we estimated change by comparing ob-
erved use summed across the 30-month post listing period (23
onths for hospitalizations) to the corresponding sum of pre-
icted values using a 10,000-iteration process. A single iteration of
he process involved generating 30 values randomly selected from
ormal distributions defined by the predicted values and respec-
ive standard errors from the linear regression model [21]. Change
as estimated as the difference between the sum of observed val-
es and the sum of the generated values. This process was re-
eated 10,000 times. Kernel density estimation was used to iden-
ify a normal density function for the 10,000 values, and then the
ean, upper 95%, and lower 95% confidence limits were extracted
rom the density. All analyses were completed using SAS versions
.1.2 (SAS Institute Inc., Cary, NC).
Results
IAC medication use followed a distinct circannual pattern peaking
in December and January and bottoming in July and August of
each year (Fig. 1). The addition of tiotropium to the PharmaCare
formulary was associated with a significant increase in its use and
a significant decrease in ipratropium use than was predicted from
use in the 3 years before the policy. In the 2 years after the policy,
tiotropium use increased approximately 70% to 0.128 daily doses
per resident per month in December 2009, compared to 0.075 daily
doses per resident per month in June 2007. Tiotropium use was
increasing before PharmaCare listing and was expected to in-
crease to 0.098 daily doses per resident per month by December
2009 in absence of the policy (95% confidence interval [CI] 0.095–
0.100). In total over the post-listing period, tiotropium use in-
creased by 24.4% (95% CI 23.9–24.8) more than predicted (Table 1).
Ipratropium use decreased 9.9% more than predicted during the
same period (95% CI 9.4 to 10.3). Total IAC medication use re-
mained approximately unchanged despite the shift from tiotro-
Table 1 – Change in health-care use after provincial drug c
Use component Units Predicted in post listing period†
95% low Base 95% high
Inhaled anticholinergic
medications
No. of daily doses 16,918,322 16,998,218 17,078,889
Tiotropium No. of daily doses 4,964,634 4,982,049 4,999,587
Ipratropium No. of daily doses 11,953,688 12,016,169 12,079,302
Physician visits§ No. of visits 2,045,315 2,073,233 2,101,925
Hospitalizations
Any hospital
admission
No. of admissions 42,067 42,735 43,424
Emergency COPD
admission
No. of admissions 6487 6658 6838
COPD, chronic obstructive pulmonary disease.
* Observed use in the BC PharmaNet database (July 2007–December 2
2009), and hospitalization database (July 2007–March 2009). The den
or older. The denominator for physician visits and hospitalizations
an inhaled anticholinergic and 60 days past the end of their last an
† Predicted from linear regression on pre-policy data (July 2004–June
‡ Each change and 95% confidence limit were estimated using a 10,0
bution defined by the predicted values and their standard errors, an
value.
§ Fee-for-service visits for any reason. Multiple services for the sam
 Admissions through a hospital emergency department where the primapium to ipratropium. Although use of ipratropium and tiotropium
was significantly changed in the post listing period, the
policy-enabled shift between the two medications occurred
mostly in the first 6 months and appeared to stabilize thereafter
(Fig. 1).
Policy changes that produce changes in prescribing can be ex-
pected to modestly increase visits to physicians because some pa-
tients who switch medications are initially monitored more closely.
Physician visits did not appear to change significantly after the Phar-
maCare listing of tiotropium (Fig. 2). Over a 2.5-year post listing pe-
riod, a mean of 67.7 visits per patient was observed, which was
within the 95% CI of predicted use from the pre-policy data.
Additional drug coverage should ideally lead to reduced de-
mand for health-care services such as physician use (not with-
standing short-term increases for monitoring medication switch-
ing) and hospitalizations or improvements in survival and quality of
life. A reduction in hospitalizations was not observed in our time
series analyses. Both emergency hospitalization for COPD (Fig. 2) and
all-cause hospitalizations increased above predicted levels from pre-
policy data. The number of emergency COPD admissions per IAC
medication patient expected over 1.75 years of follow-up was 0.206
(95% CI 0.200–0.212). Observed admissions were higher than this
range at 0.230. In total, there were between 596 and 948 more emer-
gency COPD admissions and between 582 and 1940 more hospital
admissions of any kind over the first 1.75 years of the policy than
were predicted from prepolicy data (Table 1).
There was already a substantial upward trend in IAC medica-
tion costs before tiotropium was listed by PharmaCare (Fig. 3).
Over the first 2.5 years of the policy, total cost of IAC medications
increased slightly more than predicted, by between an additional
CDN$1.30 million and CDN$1.71 million (Table 2). However, by
covering tiotropium for some patients, BC PharmaCare lowered
the total amount of out-of-pocket spending for its residents by
CDN$2.97 million (95% CI 2.83–3.11), or 19.4%. Spending on IAC
medications by PharmaCare in patients 45 years and older in-
creased between CDN$4.41 million and CDN$4.54 million over the
first 2.5 years of the listing, and spending for hospitalizations in-
creased between CDN$3.88 million and CDN$12.93 million over
the first 1.75 years of the policy (Table 2).
age for tiotropium bromide (July 2007–December 2009*).
served* Observed decrease or increase from predicted‡ P value
From 95% low From base From 95% high
026,836 108,514 0.6% 28,618 0.2% 52,053 0.3% 0.483
196,558 1,231,924 24.8% 1,214,509 24.4% 1,196,971 23.9% 0.001
830,278 1,123,410 9.4% 1,185,891 9.9% 1,249,024 10.3% 0.001
094,360 49,045 2.4% 21,126 1.0% 7565 0.4% 0.138
44,007 1940 4.6% 1272 3.0% 582 1.3% 0.001
7434 948 14.6% 776 11.7% 596 8.7% 0.001
Medical Services Plan Fee-For-Service database (July 2007–December
ator for inhaled anticholinergic use was all residents 45 years of age
residents 45 years of age or older, between their first prescriptions for
linergic.
).
eration process that randomly selected values from a normal distri-
calculated the difference between the drawn value and the observed
ent on the same day were counted as one visit.over
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604 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 0 0 – 6 0 6We generated control charts to examine the suitability of using
pre-policy data to predict post-policy utilization. These analyses are
provided in Appendix 1 (IAC use), Appendix 2 (hospital and physician
use), and Appendix 3. (prescription costs). The appendices, which
can be found at doi:10.1016/j.val.2010.11.018, show that our regres-
sion models explained nearly all of the variability in the pre-policy
data, as demonstrated by R2 statistics that were close to unity.
Discussion
Our time series analyses provided support for some but not all of our
hypotheses. As expected, use of tiotropium increased and ipratro-
pium decreased after the policy change. We did not hypothesize
magnitudes of change before the analysis due to the unique nature of
the prior authorization criteria. Suffice it to say, changes in IAC med-
ication use were not surprising nor were the changes in the amounts
paid out-of-pocket by patients or by PharmaCare. Overall, there was
no significant increase in IAC medication use (tiotropium and ipra-
tropium together) in the 2.5 years after the policy. This suggests that
increased tiotropium use was fully substituting for decreased ipra-
tropium use. In the last few months of the study period (October 2009
to December 2009) there was an apparent increase in IAC medication
use above expected levels. The apparent increase may have been
caused by a new physician fee incentive program for managing COPD
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Pre-policy
Fig. 2 – Physician visits and emergency chronic obstructive p
coverage for tiotropium bromide (July 2004–March 2009).patients, which was implemented by the provincial Ministry of tHealth on September 15, 2009. Total spending on IAC medications
(regardless of payer) did not increase dramatically beyond levels pre-
dicted from pre-policy data. This was unexpected because Pharma-
Care coverage should have allowed additional patients who could
not afford tiotropium to gain access to the drug.
A substantial benefit of tiotropium over ipratropium in terms
of reduced hospitalizations should be observable in a time series
analysis with a stable pre-policy period and in the absence of
strong co-intervening factors. For example, if tiotropium actually
reduced hospitalizations by 10% to 25% over 2 years compared to
ipratropium in similar patients, then based on the more than twofold
increase in the proportion of IAC medication use accounted for by
tiotropium over the study period (0.17–0.38), a decrease in emer-
gency hospitalizations in the range of 3% to 6% should have been
observable. Under a reasonable assumption that higher risk patients
are more likely to benefit from treatment, reductions could have
been even greater because the PharmaCare prior authorization crite-
ria focused coverage on patients with moderate to severe COPD (FEV1
as a percentage of predicted 65). Our results that all-cause hospi-
alizations and emergency hospitalizations for COPD increased
bove expected levels based on prepolicy data run contrary to a hy-
othesis of benefit in those events. Our data are possibly incompati-
le with other research suggesting time to first hospitalization for a
OPD exacerbation could increase for tiotropium compared to ipra-
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605V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 0 0 – 6 0 6some studies but not others suggests that the health effects of IAC
medication use in usual practice in BC may be different from the
effects observed in some clinical trials due to differences in patient
factors, such as comorbid conditions adherence to treatment, and
differences in how physicians manage COPD patients. The absence
of reductions in hospitalizations and physician visits in BC coinciding
with increased tiotropium use could have been due to patient factors
such as nonadherence to treatment instructions as well as use in
patients for whom the drugs are of little or no benefit. It could also
have been that tiotropium in usual practice had little or no advantage
over ipratropium in improving those measures. A systematic review
of tiotropium cost-effectiveness concluded that tiotropium is either
cost-saving or cost-effective compared to other maintenance mono-
therapies [24]. However, the review, which used mostly data from
randomized trials, also found that total costs were lower with tiotro-
pium in some but not all studies included in the analysis. The review
was also limited by the wide variety of outcome measures used in the
contributing studies. The uncertainty around the relative benefits of
tiotropium over ipratropium across other studies prevents us from
decisively establishing the compatibility of our results with an ac-
cepted consensus. At the same time, there is little reason to believe
that our results are in any way implausible.
Our study has some limitations that merit discussion. First, the
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Fig. 3 – Prescription costs and out-of-pocket spending for inh
Columbia 45 years of age and older, before and after provincstrength of evidence provided from a time series analysis is lessthan that from a randomized trial or well-designed cohort study.
The reason is an inherent weakness of time series studies to bias
from co-interventions, which are any factors unadjusted for in the
analysis, which lead to spurious results when they coincide with
the exposure of interest and independently influence the depen-
dent variable. A hypothetical example of a co-intervention would
be an outbreak of a particularly deadly strain of influenza virus
that coincided with the listing policy.
Susceptibility of our models to unknown co-interventions
means our hospitalization results should only be considered as a
potential signal worthy of further investigation rather than un-
equivocal evidence of harm. Another important limitation was
that we did not consider other health measures such as mortality,
COPD exacerbations, or quality of life. Those metrics were not
measurable in our data but are important to patients, caregivers,
insurers, and other members of society. In addition, the wider
potential economic effects of covering the newer and patented
tiotropium medication were also outside the scope of this analysis
but potentially important from a societal perspective.
The main measurable benefits of public drug plan coverage for
tiotropium in BC were a reduction in out-of-pocket costs for patients
and their private insurers. Before versus after time series analysis did
not show a reduction in hospitalizations or physician visits or their
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could be an important signal that merits further investigation.
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